| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Hypertrophic | 158 | 2026 | 802 | 27.990 |
Why?
|
| Atrial Fibrillation | 26 | 2026 | 884 | 6.220 |
Why?
|
| Ventricular Outflow Obstruction | 19 | 2025 | 118 | 5.510 |
Why?
|
| Death, Sudden, Cardiac | 52 | 2026 | 367 | 5.380 |
Why?
|
| Defibrillators, Implantable | 30 | 2024 | 273 | 4.850 |
Why?
|
| Magnetic Resonance Imaging, Cine | 23 | 2026 | 115 | 4.330 |
Why?
|
| Heart Failure | 29 | 2026 | 968 | 4.010 |
Why?
|
| Tachycardia, Ventricular | 11 | 2024 | 131 | 3.050 |
Why?
|
| Anti-Arrhythmia Agents | 8 | 2026 | 102 | 2.520 |
Why?
|
| Catheter Ablation | 5 | 2026 | 160 | 2.470 |
Why?
|
| Ventricular Septum | 8 | 2022 | 30 | 2.460 |
Why?
|
| Myocardium | 15 | 2026 | 302 | 2.230 |
Why?
|
| Humans | 182 | 2026 | 65831 | 2.220 |
Why?
|
| Contrast Media | 17 | 2026 | 435 | 2.170 |
Why?
|
| Electric Countershock | 9 | 2026 | 109 | 2.000 |
Why?
|
| Cardiac Surgical Procedures | 15 | 2023 | 272 | 1.950 |
Why?
|
| Middle Aged | 77 | 2026 | 18495 | 1.950 |
Why?
|
| Risk Assessment | 22 | 2025 | 2114 | 1.910 |
Why?
|
| Heart Transplantation | 10 | 2024 | 180 | 1.840 |
Why?
|
| Gadolinium | 12 | 2024 | 111 | 1.840 |
Why?
|
| Electrocardiography | 12 | 2024 | 556 | 1.760 |
Why?
|
| Male | 91 | 2026 | 31403 | 1.750 |
Why?
|
| Risk Factors | 43 | 2026 | 5472 | 1.720 |
Why?
|
| Heart Septum | 10 | 2022 | 57 | 1.640 |
Why?
|
| Exercise Test | 5 | 2026 | 257 | 1.610 |
Why?
|
| Heart Aneurysm | 6 | 2021 | 23 | 1.550 |
Why?
|
| Adult | 67 | 2026 | 17571 | 1.520 |
Why?
|
| Female | 79 | 2026 | 34419 | 1.480 |
Why?
|
| Treatment Outcome | 31 | 2026 | 5831 | 1.480 |
Why?
|
| Retrospective Studies | 34 | 2026 | 6952 | 1.470 |
Why?
|
| Ablation Techniques | 5 | 2020 | 26 | 1.430 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2021 | 171 | 1.420 |
Why?
|
| Echocardiography | 14 | 2026 | 513 | 1.400 |
Why?
|
| Amyloidosis | 3 | 2022 | 70 | 1.390 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 137 | 1.390 |
Why?
|
| Aged | 46 | 2026 | 15143 | 1.390 |
Why?
|
| Ventricular Fibrillation | 8 | 2023 | 108 | 1.340 |
Why?
|
| Follow-Up Studies | 18 | 2026 | 2497 | 1.330 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2023 | 2324 | 1.320 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 5 | 2023 | 28 | 1.190 |
Why?
|
| Heart Ventricles | 10 | 2022 | 267 | 1.070 |
Why?
|
| Ventricular Function, Left | 14 | 2026 | 284 | 1.060 |
Why?
|
| Primary Prevention | 4 | 2021 | 137 | 1.050 |
Why?
|
| Disopyramide | 2 | 2025 | 11 | 1.040 |
Why?
|
| Young Adult | 29 | 2025 | 4881 | 1.030 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2024 | 46 | 0.960 |
Why?
|
| Vascular Diseases | 2 | 2024 | 83 | 0.950 |
Why?
|
| Heart Atria | 2 | 2026 | 137 | 0.920 |
Why?
|
| Symptom Assessment | 1 | 2026 | 48 | 0.920 |
Why?
|
| Stroke | 4 | 2024 | 1225 | 0.920 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 20 | 0.910 |
Why?
|
| Predictive Value of Tests | 20 | 2026 | 1117 | 0.890 |
Why?
|
| Mitral Valve | 5 | 2023 | 126 | 0.890 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 30 | 0.870 |
Why?
|
| Survival Rate | 11 | 2024 | 849 | 0.860 |
Why?
|
| Athletes | 7 | 2024 | 109 | 0.840 |
Why?
|
| Papillary Muscles | 2 | 2015 | 16 | 0.830 |
Why?
|
| Quality of Life | 7 | 2024 | 1267 | 0.810 |
Why?
|
| Precision Medicine | 2 | 2022 | 134 | 0.810 |
Why?
|
| Stroke Volume | 10 | 2026 | 346 | 0.790 |
Why?
|
| Prognosis | 22 | 2026 | 1794 | 0.780 |
Why?
|
| Phenotype | 15 | 2024 | 1236 | 0.770 |
Why?
|
| Atrial Appendage | 1 | 2024 | 41 | 0.770 |
Why?
|
| Cicatrix | 8 | 2026 | 62 | 0.730 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2020 | 20 | 0.730 |
Why?
|
| Cardiovascular System | 1 | 2022 | 41 | 0.710 |
Why?
|
| Return to Sport | 2 | 2021 | 14 | 0.710 |
Why?
|
| Adolescent | 20 | 2025 | 6367 | 0.670 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 107 | 0.670 |
Why?
|
| Disease Progression | 9 | 2026 | 1229 | 0.640 |
Why?
|
| Hemodynamics | 3 | 2017 | 253 | 0.630 |
Why?
|
| Time Factors | 14 | 2026 | 3777 | 0.620 |
Why?
|
| Longevity | 2 | 2017 | 118 | 0.600 |
Why?
|
| Aortic Valve | 2 | 2020 | 181 | 0.590 |
Why?
|
| Cardiotonic Agents | 3 | 2018 | 54 | 0.590 |
Why?
|
| Sports | 4 | 2024 | 98 | 0.590 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2023 | 124 | 0.590 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 61 | 0.580 |
Why?
|
| Exercise Tolerance | 2 | 2025 | 85 | 0.570 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 16 | 0.570 |
Why?
|
| Incidence | 7 | 2026 | 1432 | 0.560 |
Why?
|
| Referral and Consultation | 2 | 2019 | 447 | 0.560 |
Why?
|
| Child | 16 | 2024 | 4651 | 0.550 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 110 | 0.540 |
Why?
|
| Echocardiography, Stress | 1 | 2017 | 15 | 0.530 |
Why?
|
| Waiting Lists | 1 | 2018 | 55 | 0.530 |
Why?
|
| Kidney Diseases | 1 | 2019 | 178 | 0.530 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 171 | 0.520 |
Why?
|
| Critical Pathways | 1 | 2017 | 31 | 0.520 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 190 | 0.510 |
Why?
|
| Heart | 6 | 2024 | 298 | 0.510 |
Why?
|
| Guideline Adherence | 1 | 2019 | 310 | 0.500 |
Why?
|
| Cohort Studies | 11 | 2026 | 2650 | 0.500 |
Why?
|
| Obesity | 1 | 2025 | 1281 | 0.490 |
Why?
|
| Systole | 5 | 2021 | 109 | 0.480 |
Why?
|
| Fibrosis | 8 | 2024 | 172 | 0.470 |
Why?
|
| Mutation | 10 | 2024 | 2674 | 0.450 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2022 | 279 | 0.450 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 158 | 0.450 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 25 | 0.450 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2026 | 190 | 0.440 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 5682 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 741 | 0.440 |
Why?
|
| Angina, Stable | 1 | 2014 | 11 | 0.430 |
Why?
|
| Disease Management | 6 | 2020 | 235 | 0.430 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 41 | 0.410 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2022 | 20 | 0.400 |
Why?
|
| Coronary Vessels | 1 | 2014 | 125 | 0.400 |
Why?
|
| Heart Failure, Diastolic | 1 | 2013 | 9 | 0.400 |
Why?
|
| Coronary Angiography | 1 | 2014 | 212 | 0.400 |
Why?
|
| Electrodes | 1 | 2013 | 39 | 0.380 |
Why?
|
| Scalp | 1 | 2013 | 30 | 0.380 |
Why?
|
| Ambulatory Care | 1 | 2014 | 318 | 0.360 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 170 | 0.350 |
Why?
|
| Anticoagulants | 4 | 2024 | 529 | 0.350 |
Why?
|
| Oxygen Consumption | 2 | 2026 | 213 | 0.340 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 465 | 0.340 |
Why?
|
| Benzylamines | 2 | 2022 | 35 | 0.340 |
Why?
|
| Recurrence | 2 | 2026 | 665 | 0.320 |
Why?
|
| Recovery of Function | 4 | 2019 | 293 | 0.310 |
Why?
|
| Heart Arrest | 2 | 2022 | 177 | 0.310 |
Why?
|
| United States | 12 | 2026 | 8189 | 0.310 |
Why?
|
| Global Health | 4 | 2026 | 181 | 0.310 |
Why?
|
| Genotype | 5 | 2026 | 676 | 0.300 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1569 | 0.290 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 100 | 0.290 |
Why?
|
| Risk Management | 1 | 2008 | 37 | 0.280 |
Why?
|
| Demography | 2 | 2026 | 178 | 0.270 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 60 | 0.270 |
Why?
|
| Massachusetts | 3 | 2020 | 2158 | 0.270 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1439 | 0.270 |
Why?
|
| Hospitalization | 2 | 2026 | 1404 | 0.270 |
Why?
|
| Adipose Tissue | 1 | 2010 | 301 | 0.270 |
Why?
|
| Nursing Staff, Hospital | 1 | 2008 | 78 | 0.260 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2019 | 117 | 0.260 |
Why?
|
| Comorbidity | 2 | 2021 | 1122 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1665 | 0.250 |
Why?
|
| Mass Screening | 1 | 2012 | 700 | 0.240 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 293 | 0.240 |
Why?
|
| Medical Errors | 1 | 2008 | 202 | 0.240 |
Why?
|
| Bibliometrics | 1 | 2026 | 35 | 0.240 |
Why?
|
| Coronary Circulation | 1 | 2025 | 55 | 0.230 |
Why?
|
| Cardiology | 2 | 2019 | 172 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2026 | 736 | 0.220 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2025 | 53 | 0.220 |
Why?
|
| Gadolinium DTPA | 4 | 2018 | 84 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 876 | 0.210 |
Why?
|
| Asymptomatic Diseases | 3 | 2026 | 52 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2026 | 888 | 0.210 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 11 | 0.210 |
Why?
|
| Age Factors | 5 | 2024 | 1595 | 0.210 |
Why?
|
| Uracil | 2 | 2022 | 36 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1291 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2025 | 3339 | 0.200 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2022 | 100 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 746 | 0.200 |
Why?
|
| Reproducibility of Results | 7 | 2026 | 1719 | 0.200 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 170 | 0.200 |
Why?
|
| Periodicals as Topic | 1 | 2026 | 178 | 0.200 |
Why?
|
| Death, Sudden | 1 | 2023 | 31 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 192 | 0.190 |
Why?
|
| Patient Selection | 5 | 2018 | 484 | 0.190 |
Why?
|
| Soccer | 1 | 2022 | 13 | 0.190 |
Why?
|
| Prealbumin | 1 | 2022 | 21 | 0.190 |
Why?
|
| Interatrial Block | 1 | 2022 | 2 | 0.190 |
Why?
|
| Boston | 2 | 2020 | 259 | 0.180 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 94 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 995 | 0.180 |
Why?
|
| Consensus | 2 | 2021 | 174 | 0.180 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2021 | 17 | 0.180 |
Why?
|
| Echocardiography, Doppler | 3 | 2017 | 134 | 0.170 |
Why?
|
| Embolization, Therapeutic | 2 | 2015 | 338 | 0.170 |
Why?
|
| Writing | 1 | 2021 | 44 | 0.170 |
Why?
|
| Ontario | 1 | 2021 | 57 | 0.170 |
Why?
|
| One Health | 1 | 2021 | 2 | 0.170 |
Why?
|
| Heart Conduction System | 1 | 2021 | 50 | 0.170 |
Why?
|
| Sarcomeres | 4 | 2022 | 53 | 0.170 |
Why?
|
| Prevalence | 6 | 2023 | 1453 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 161 | 0.160 |
Why?
|
| Image Enhancement | 3 | 2021 | 196 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2021 | 98 | 0.160 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2020 | 7 | 0.160 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 2 | 2017 | 17 | 0.160 |
Why?
|
| Judgment | 1 | 2020 | 37 | 0.160 |
Why?
|
| Reference Standards | 1 | 2020 | 77 | 0.160 |
Why?
|
| Syncope | 1 | 2020 | 42 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 59 | 0.160 |
Why?
|
| Proteome | 1 | 2021 | 153 | 0.150 |
Why?
|
| Diseases in Twins | 1 | 2020 | 56 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 312 | 0.150 |
Why?
|
| Safety | 1 | 2020 | 142 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 131 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 160 | 0.150 |
Why?
|
| Ethanol | 2 | 2020 | 333 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 152 | 0.150 |
Why?
|
| Genomics | 1 | 2022 | 387 | 0.150 |
Why?
|
| Sex Factors | 2 | 2019 | 995 | 0.140 |
Why?
|
| Patients | 1 | 2020 | 117 | 0.140 |
Why?
|
| Europe | 4 | 2024 | 200 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 122 | 0.140 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2018 | 40 | 0.140 |
Why?
|
| Myocardial Reperfusion | 1 | 2018 | 23 | 0.140 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2017 | 28 | 0.140 |
Why?
|
| Health Status | 2 | 2018 | 448 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 1502 | 0.130 |
Why?
|
| Sotalol | 1 | 2017 | 9 | 0.130 |
Why?
|
| Fabry Disease | 1 | 2017 | 8 | 0.130 |
Why?
|
| Amiodarone | 1 | 2017 | 22 | 0.130 |
Why?
|
| Hypertension | 1 | 2023 | 618 | 0.130 |
Why?
|
| Cardiac Myosins | 1 | 2017 | 25 | 0.120 |
Why?
|
| Myosin Heavy Chains | 1 | 2017 | 48 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2018 | 169 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2018 | 147 | 0.120 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 111 | 0.120 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 96 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2017 | 579 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 745 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 162 | 0.120 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 80 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2017 | 719 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 88 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 537 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 488 | 0.110 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mortality | 3 | 2025 | 162 | 0.100 |
Why?
|
| Inflammation | 1 | 2021 | 1199 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 309 | 0.100 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 28 | 0.100 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2013 | 45 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 413 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 401 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2012 | 41 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2738 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 922 | 0.090 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 292 | 0.080 |
Why?
|
| Cause of Death | 2 | 2025 | 221 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2024 | 144 | 0.080 |
Why?
|
| Biopsy | 1 | 2010 | 463 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1146 | 0.070 |
Why?
|
| Hospitals, Voluntary | 1 | 2008 | 1 | 0.070 |
Why?
|
| Medical Informatics Applications | 1 | 2008 | 13 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2017 | 24 | 0.060 |
Why?
|
| Pedigree | 2 | 2017 | 193 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2025 | 70 | 0.060 |
Why?
|
| Internet | 1 | 2008 | 472 | 0.050 |
Why?
|
| Bundle-Branch Block | 1 | 2024 | 15 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2024 | 58 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 935 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 198 | 0.050 |
Why?
|
| Universities | 1 | 2024 | 169 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 593 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2023 | 130 | 0.050 |
Why?
|
| Vascular Remodeling | 1 | 2022 | 23 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2024 | 757 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 1029 | 0.040 |
Why?
|
| Darkness | 1 | 2021 | 20 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2021 | 11 | 0.040 |
Why?
|
| Cell Communication | 1 | 2022 | 135 | 0.040 |
Why?
|
| Endophenotypes | 1 | 2021 | 9 | 0.040 |
Why?
|
| Workload | 1 | 2022 | 132 | 0.040 |
Why?
|
| Multi-Institutional Systems | 1 | 2020 | 5 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 35 | 0.040 |
Why?
|
| Publication Bias | 1 | 2020 | 21 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 148 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 414 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 110 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 34 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 56 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 8 | 0.040 |
Why?
|
| Pandemics | 1 | 2025 | 692 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2020 | 73 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 34 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 197 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 127 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 242 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 374 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 216 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 274 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 130 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 165 | 0.030 |
Why?
|
| New Jersey | 1 | 2018 | 24 | 0.030 |
Why?
|
| alpha-Galactosidase | 1 | 2017 | 8 | 0.030 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 12 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 131 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 78 | 0.030 |
Why?
|
| Ventricular Function | 1 | 2017 | 22 | 0.030 |
Why?
|
| Dyspnea | 1 | 2018 | 120 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 398 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 408 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2017 | 47 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 145 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2017 | 81 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 113 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 213 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 157 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 21491 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 120 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 95 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 2005 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 196 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 395 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1336 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 69 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 201 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 335 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 222 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 73 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 364 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 427 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 74 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 142 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 88 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 202 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 606 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 932 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 413 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 405 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 296 | 0.020 |
Why?
|
| Minnesota | 1 | 2012 | 47 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 2089 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 420 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 3169 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2018 | 852 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2016 | 926 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 715 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 11185 | 0.010 |
Why?
|